Julianna Pherarolis

Julianna Pherarolis

25 Jun, 2025

“I am incredibly satisfied with the work Celegence has done thus far. They communicate well and receive feedback well. I find the team I have been assigned incredibly easy to work with, friendly, and people I genuinely look forward to speaking with once a week.”

Other Related Articles

A Strategic Guide to PMS, eAF, ePI, eCTD 4.0. and ESMP

Blog Pharmaceutical

A Strategic Guide to PMS, eAF, ePI, eCTD 4.0. and ESMP

21 May, 2026

Devices Incorporating Tissues or Cells of Animal or Human Origin, or Their Derivatives: Data Expectations Under EU MDR

Blog Medical Devices

Devices Incorporating Tissues or Cells of Animal or Human Origin, or Their Derivatives: Data Expectations Under EU MDR

13 May, 2026

Nitrosamine Control Insights: Clarity and Control in EU Risk Assessment

Blog Pharmaceutical

Nitrosamine Control Insights: Clarity and Control in EU Risk Assessment

07 May, 2026

PMCF Under MDR: When is a Healthcare Professional Survey Approach Justifiable?

Blog Medical Devices

PMCF Under MDR: When is a Healthcare Professional Survey Approach Justifiable?

29 Apr, 2026

Dental Medical Devices: Special Considerations for Clinical Evaluation Under EU MDR

Blog Medical Devices

Dental Medical Devices: Special Considerations for Clinical Evaluation Under EU MDR

22 Apr, 2026

MDR Article 117: What It Means — And How We Help You Get Ahead

Blog Medical Devices

MDR Article 117: What It Means — And How We Help You Get Ahead

16 Apr, 2026

Heavy Metals in Pharmaceuticals: A Critical Quality and Safety Imperative

Blog Pharmaceutical

Heavy Metals in Pharmaceuticals: A Critical Quality and Safety Imperative

10 Apr, 2026

EMA Roadmap Update: PMS Capabilities and the End of the Legacy Era

Blog Pharmaceutical

EMA Roadmap Update: PMS Capabilities and the End of the Legacy Era

01 Apr, 2026

View All